EGFR and non-small cell lung carcinoma: Highly heterogeneous tumors possess a diversity of genetic alterations, which can include oncogenic variants that mediate resistance to targeted therapies [117], such as in EGFR-mutated NSCLC [118] or BRAF-mutated melanoma [119].